Developing selective IRF modulators would help overcome the therapeutic limitations imposed by functional redundancy and heterogeneity, driving the evolution of AD immunotherapy from “broad-spectrum anti-inflammation” toward “precise immune remodeling”. The gene discussed is TRIM63; the disease is Alzheimer disease.